Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

EUROCARE-3 – new European cancer survival figures

25.09.2003


Survival figures for cancer in Europe show large differences between countries – more than can reasonably be accounted for by artefact, bias or chance, according to the authors of the EUROCARE-3 study “Cancer survival in Europe at the end of the 20th century”.



A preview of some highlights of the study, which was co-ordinated by the Epidemiology Unit of the Istituto Nazionale Tumori, Milan, Italy and is due to be published by Annals of Oncology shortly – was presented today (Thursday 25 September) at the final day of ECCO 12 – The European Cancer Conference.

The report, which is a follow up to EUROCARE-2, published in 1999, has analysed data from registries covering all or part of 22 countries1 and 42 types of cancer. It examined five-year survival after diagnosis for 1.8 million adults and 24,000 children diagnosed during 1990-94 and followed to the end of 1999.


One of the report’s authors, Professor Michel Coleman, Professor of Epidemiology and Vital Statistics at the London School of Hygiene and Tropical Medicine, told the conference that the aim of exploring differences in cancer survival was not to establish league tables or excite national rivalries, but to estimate the range of survival rates and to identify regions or countries in which survival could be improved. “There is increasing evidence that international survival differences are at least partly due to factors that can be changed, such as stage at diagnosis, access to optimal treatment and investment in health care,” he said.

[The proportion of gross domestic product devoted to health care in the contributing countries in 1995 ranged from 6% in Poland to 10.6% in Germany, and the per capita spend varied from $420 in Poland to $2,555 in Switzerland]
Looking at Europe overall, average five-year survival rates varied from a high of 94% for lip cancer to less than 4% for pancreatic cancer.

There was an average of 80%, or better, survival for cancers of the lip, testis and thyroid and for melanoma and Hodgkin’s disease – but these cancers accounted for only 4% of adult malignancies.
About a third of cancers averaged survival rates of 60-79%. These included cancers of the breast, prostate, bladder, cervix, uterus and larynx.

For one-fifth of all cancers, the European average five-year survival was in the range 40-59% – this group included colon, rectum and kidney cancers and non-Hodgkin lymphoma.
About 10% of all cancers had poor prognosis, with an average of 20-39% five-year survival. These included stomach and ovarian cancer and multiple myeloma.

However, about a quarter of all adult cancers fell into the worst prognosis category – including cancers of the lung, pancreas, oesophagus, brain and liver. These had survival rates of less than 20%.

Childhood cancer survival was generally good with two-thirds of all affected children (13 of the 24 malignancies analysed) achieving 75% five-year survival or better.
Survival for most cancers declined steeply with age at diagnosis. Two exceptions were breast cancer, where the best survival was for women aged 45-54 and prostate cancer where it was among men aged 55-64 years.

But, even after the investigators had adjusted for differences in background mortality by age and sex between regions and countries they found large variations between countries in overall cancer survival and survival for specific cancers, as well as between men and women.
Overall survival was generally below the European average in five eastern European countries (Czech Republic, Estonia, Poland, Slovakia and Slovenia, with Poland the lowest) and in Denmark, England, Scotland, Wales, Malta and Portugal among participating western European countries. Sweden tended to have the highest survival rates among the five Nordic countries, while the areas of France and Switzerland covered by the study often had the highest survival rates among western European populations.

For men, the all-cancers survival index ranged from 25 to 32% in eastern European populations and from 40 to 47% in most of the Nordic and western European populations. For England, Scotland, Wales and Denmark the range was from 33 to 37%, slightly below the European average of 38%.

For women, the range was from 41 to 47% in eastern European countries and in the narrow range of 55 to 58% in ten of the Nordic and western European countries. For England, Scotland, Wales and Denmark the range was from 47 to 51%, slightly below the European average of 52%.
However, while survival in the UK and Denmark was generally below the European average, these countries had either above or about average survival rates for melanoma, testicular cancer and Hodgkin’s disease – illustrating how countries performed differently for different cancers.

Some cancers showed particularly wide differences in survival. Lung cancer varied more than two-fold although the best rates were still under 15%. In some cancers there was evidence that the nature of the cancer was contributing to differences. For example, stomach cancer survival was higher in western Europe where incidence is high than in the Nordic countries and the UK where incidence is lower. Survival was relatively high in southern Europe because of a higher proportion of tumours in which either the location of the tumour or the specific type of tumour conferred a better prognosis.

For 30 of the 35 cancers examined that occur in both sexes, survival was higher in women. According to the researchers the advantage among women was most likely to arise from sex differences in tumour biology, immune system mechanisms, symptom awareness, stage of disease at diagnosis or access to effective treatment.

Turning to time trends since the mid-1980s, one of the most worrying aspects was the widening gap in cancer survival between eastern Europe and other parts of Europe. Breast cancer survival improved steadily in all European countries, with evidence that some western European countries with previously poorer survival were catching up. But, improvements were less marked for eastern Europe, so the gap between east and west has actually increased

For colorectal cancer the gap between the higher Nordic survival figures and western Europe is also closing, but again the gap between west and east is widening.
Prostate cancer survival trends vary widely, with survival increasing in most countries. Five-year survival increased in the Nordic countries, except Denmark, and there were sharp improvements in France, Germany, Italy, England, Scotland and Wales. Trends were more diverse in eastern Europe, with a rapid increase in Estonia but a decline in Poland and Slovakia. The trends appear mostly to reflect international differences in the use of Prostate-Specific Antigen (PSA) as a diagnostic test, and the increases cannot all be interpreted as a better outcome for men with this cancer.

Professor Coleman said that although European survival trends for all cancers combined were not adjusted for differences in the case-mix between countries, they were remarkably consistent and appeared to offer an overall indicator of the performance of health care systems in each country.
He sounded a warning note for the future on the east-west divide. “The survival trends reflect a substantial and increasing gap in the overall prognosis of cancer between eastern and western Europe. Since all five eastern European countries participating in EUROCARE will probably join the EU in 2004, this raises a major new problem of inequity in health within the EU.

Professor Coleman added that “The wide differences in survival trends are likely to reflect differences in both stage at diagnosis and the availability of and access to health resources, both of which are amenable to intervention. They represent a benchmark for reduction in inequalities in cancer survival across Europe in the future. While we do not yet have a fully satisfactory interpretation of these differences, we have few alternatives to this type of study and we believe this is a vital contribution towards the ongoing efforts to improve survival in Europe. The EUROCARE team is actively inviting independent clinical commentary on the study. Generating an appropriate level of concern to address this problem would be an important outcome of the EUROCARE project.”

Mary Rice | European Cancer Conference
Further information:
http://www.fecs.be/conferences/ecco12/media_updates.shtml

More articles from Health and Medicine:

nachricht Vanishing capillaries
23.03.2017 | Technische Universität München

nachricht How prenatal maternal infections may affect genetic factors in Autism spectrum disorder
22.03.2017 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

When Air is in Short Supply - Shedding light on plant stress reactions when oxygen runs short

23.03.2017 | Life Sciences

Researchers use light to remotely control curvature of plastics

23.03.2017 | Power and Electrical Engineering

Sea ice extent sinks to record lows at both poles

23.03.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>